Ongoing phase II studies are currently investigating the effects of midostaurin in combination with chemotherapy specifically in patients with FLT3/ITD mutation (NCT01477606) and in combination with decitabine in elderly AML patients (NCT02634827; NCT01846624). The gene discussed is FLT3; the disease is acute myeloid leukemia.